PhaseBio Pharmaceuticals Revenue

Revenue of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Revenue growth rates and interactive chart. Revenue is the income generated from normal business operations and includes discounts and deductions for returned merchandise. It is the top line or gross income figure from which costs are subtracted to determine net income.

Highlights and Quick Summary

  • Revenue for the quarter ending September 29, 2021 was $335 Thousand (a -96.76% decrease compared to previous quarter)
  • Year-over-year quarterly Revenue decreased by -56.15%
  • Annual Revenue for 2020 was $320 Thousand (a -44.35% decrease from previous year)
  • Annual Revenue for 2019 was $575 Thousand (a -13.92% decrease from previous year)
  • Twelve month Revenue ending September 29, 2021 was $11.8 Million (a 0.81% increase compared to previous quarter)
  • Twelve month trailing Revenue increased by 397.97% year-over-year
Trailing Revenue for the last four month:
29 Sep '21 29 Jun '21 30 Mar '20 30 Dec '19
$11.8 Million $11.7 Million $2.03 Million $2.36 Million
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Revenue of PhaseBio Pharmaceuticals

Most recent Revenueof PHAS including historical data for past 10 years.

Interactive Chart of Revenue of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals Revenue for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $0.34 $10.34
2020 $0.32 $0.32
2019 $0.76 $0.24 $0.7 $0.65 $0.58
2018 $0.26 $0.41 $0.67

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.